Spero therapeutics announces fda acceptance and priority review of new drug application for tebipenem hbr for the treatment of complicated urinary tract infections including pyelonephritis

The fda has set a prescription drug user fee act (pdufa) target action date of june 27, 2022 the fda has set a prescription drug user fee act (pdufa) target action date of june 27, 2022

SPRO Ratings Summary

SPRO Quant Ranking